Drug-development-2020

December 10, 2020

Drug-development-2020

Theme: "Accelerate Drug Development and identify new methods of Drug Designing"

Webinar on Drug Development invites all the global leaders and researchers to share their research at this exclusive scientific program held during December 10th, 2020, which based on the theme “Accelerate Drug Development and identify new methods of Drug Designing”.

Scientific Sessions of Drug Development includes Drug Delivery and Targeting, Drug Discovery and Development, Nanotechnology in Drug Discovery, Cardiovascular Drug Discovery, Drug Discovery in Preclinical Research, Drug Designing and Molecular Modelling, Novel Therapeutics in Drug Designing, Clinical Trials and Regulatory Affairs, Medicinal Chemistry in Modern Drug Discovery, Pharmaceutical Research and Development, Natural products Drug Discovery.

The Drug Development Webinar has a strong emphasis on support and inspiration for the next generation of scientists, along with early-career researchers, a Young Researchers Forum, and activities to encourage interaction with peers and experts. Altogether this conference aims to be an extraordinary cross discipline gathering in the Drug Development life sciences for research presentations, discussions, learning’s, inspirations and encouragement with participants leaving with new research knowledge and ideas, and perhaps the beginnings of international collaborations and associations.

 

Scientific Session:

Session 1:  Drug Delivery and Targeting

Targeted drug delivery (TDD) is emerging as a powerful tool for the treatment of cancer because of enhanced delivery of drugs, as well as genes, to a tumor site with protection from the extracellular environment. Stimuli-responsive nanogels (NGs) are three-dimensional hydrophilic polymer networks that are formed via covalent linkages or self-assembly processes and are able to change their structural properties in the presence of external stimuli. These NGs have been widely examined as smart drug delivery carriers for a variety of anticancer drugs, as well as genes, because of stability, ease of synthesis, good control over particle size, and easy functionalization. They can control sizes from 5 to 400 nm, followed by different polymerization conditions.

Session 2:  Drug Discovery and Development

Drug discovery is the process through which potential new medicines are recognized and comprises an extensive range of scientific disciplines, including biology, chemistry and pharmacology. The integration of pharmacodynamics and pharmacokinetic parameters in non-clinical pharmacology studies is a key characteristic in drug discovery for efficacy and safety assessment, in the particular for the translation from the non-clinical to  clinical field and process of drug discovery include  the identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy whereas modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity, efficacy/potency, metabolic stability, and oral bioavailability. The "final product" of drug discovery is a patent on the potential drug.

Session 3: Nanotechnology in Drug Discovery

Nanotechnology is a study of science and technology which targets to regulate matter at the atomic, molecular, and macromolecular level. New nanotechnologies could bring intense increases in the sensitivity of detection technology for research and diagnostic applications, improved imaging technologies, greater selectivity for drug delivery, and detailed insight into biological mechanisms and systems. Nano biosensors and Nano biochips are used to develop drug discovery and development. Nano scale assays can subsidize substantially to cost-saving in screening promotions. The practice of Nano scale delivery vehicles prominent to the discovery of optimally safe in talling to effective drug candidates, current and promising applications of Nano medicine include, drug delivery, in vitro diagnostics, in vivo imaging, therapy techniques, biomaterials, and tissue engineering.

Session 4:  Cardiovascular Drug Discovery

Cardiovascular diseases are projected to affect populace across the world. Cardiovascular diseases contain diseases and disorders related to heart and blood vessels. Numerous drugs are accessible and are under development for treating cardiovascular diseases based on various signs such as arrhythmia, myocardial infarction, and atherosclerosis. The global cardiovascular drug has been involved into many drugs. Some of the major cardiovascular drugs include anti-hypertensive drugs such as calcium channel blockers and Angiotensin II receptor antagonists, and hypolipidemic drugs.

Session 5: Drug Discovery in Preclinical Research

The chief impartial of pre-clinical studies is to define the safe dose for first-in-man study and assess a product's safety profile.  Pre-clinical development also recognized as pre-clinical studies and non-clinical studies .In the drug development, preclinical development, is a phase study which prior to earlier clinical trials can begin, and during which important possibility, iterative testing and drug safety data is composed. Generally, only one in every 5,000 compounds that arrives drug discovery to the stage of pre-clinical development befits as an approved drug. These pre-clinical studies involve local toxicity studies such as acute, sub-acute, chronic toxicity studies and systemic toxicity studies such as genotoxicity and carcinogenicity studies.

Session 6: Drug Designing and Molecular Modelling

Drug design, frequently called as rational drug design, is the resourceful process of discovering new medications based happening the knowledge of a biological target. The saying "drug design" is to also known as ligand design. This molecule design will bind tightly to its target. While design techniques for prediction of binding affinity are practically successful but there are many other properties, such as bioavailability, metabolic half-life, side effects, etc., that  must be enhanced before a ligand can become a safe and efficacious drug. The normal cost of developing new drug molecules and the period taken to market them is high. Molecular modelling methods also known as Computational methods. These techniques can be utilized to speed up drug discovery process for earning new drug molecules.

Session 7: Clinical Trials and Regulatory Affairs

Clinical trial generates data on safety and efficacy. Such consequent biomedical or behavioural research studies on human participants are designed to answer specific questions about biomedical or behavioural interferences, including new treatments such as novel vaccines, drugs, dietary supplements, and medical devices. These trials produce data on safety and efficacy. The regulatory affairs outsourcing market has been segmented into five major service sections .Those sections include regulatory affairs, clinical trial applications and product registrations, regulatory writing and publishing, regulatory consulting and legal representation and others. The market sections have been broadly scheduled on the source of their usefulness, efficacy, and generated revenue and geographic revenue.

Session 8: Medicinal Chemistry in Modern Drug Discovery

The modern drug discovery process is an overview to the development of new drugs. Now a days new biological targets, methodologies and advanced computing have enhanced modern drug discovery and have given medicinal chemistry a more thoughtful skill set and toolkit to hold the nuances  of disease pathophysiology. The medicinal chemistry related methodologies and a methodology in drug discovery improves the efficiency   in drug discovery and lessening attrition. In drug designing, Structure-based drug design, and fragment –based drug design, natural product-based drug design, diversity-based drug design, and chemo genomics are applied.

Session 9:  Pharmaceutical Research and Development

In discovery procedure comprises the initial stages of research, which are intended to recognize an investigational drug and perform primary tests in the lab. This first stage of the process takes   three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people. These developments offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used along with diagnostics, clinical trial protocols must be improved and increased.

Session 10: Natural products Drug Discovery

Natural products (secondary metabolites) have been more successful source of potential drug leads. Natural products still play a major role as starting material for drug discovery. There are several sources for natural products for drug discovery like plant sources, microbial sources, and marine sources. Natural products are very large in numbers with an excellent chemical diversity. Natural products discovery can be approached by using Cell-Based assays, Biochemical assays and newer drug discovery. Natural products have played a key role in Pharma research, as many medicines are either natural products or derivatives.

 

  • Drug Delivery and Targeting
  • Drug Discovery and Development
  • Nanotechnology in Drug Discovery
  • Cardiovascular Drug Discovery
  • Drug Discovery in Preclinical Research
  • Drug Designing and Molecular Modelling
  • Clinical Trials and Regulatory Affairs
  • Medicinal Chemistry in Modern Drug Discovery
  • Pharmaceutical Research and Development
  • Natural products Drug Discovery